6-Amino-5-bromoquinoxaline hydrobromide | 59803-96-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-Amino-5-bromoquinoxaline hydrobromide
• 英文别名: 5-bromoquinoxalin-6-amine;hydrobromide
• CAS: 59803-96-2
• 化学式: BrH*C₈H₆BrN₃
• 分子量: 304.972
• InChiKey: YKGMGCYABGHZRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.55
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Amino-5-bromoquinoxaline hydrobromide 以 水 、 苯 为溶剂， 反应 2.0h， 生成 溴莫尼定
  参考文献：
  名称：

  [EN] METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
  [FR] PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION D'UN ÉRYTHÈME AIGU

  摘要：

  提出了一种治疗或预防人类急性红斑的方法，通过局部给药有效量的α肾上腺素受体激动剂或其药用盐。首选的α肾上腺素受体激动剂是布里莫啶。还提出了一种通过局部给药有效量的α肾上腺素受体激动剂或其药用盐来预防急性红斑引起的继发性炎症的方法。

  公开号：

  WO2011053487A1
• 作为产物：
  描述：

  6-氨基喹喔啉 以100的产率得到6-Amino-5-bromoquinoxaline hydrobromide
  参考文献：
  名称：

  Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or

  摘要：

  披露了某些（2-咪唑啉-2-基氨基）喹喔啉。当直接给哺乳动物眼睛施用时，这种喹喔啉可以降低或维持眼内压力。

  公开号：

  US05021416A1

文献信息

• Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
  申请人：Allergan, Inc.

  公开号：US05373010A1

  公开（公告）日：1994-12-13

  A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## , pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as constriction of one or more blood vessels and decongestion of one or more nasal passages.

  一种治疗哺乳动物的方法包括向哺乳动物施用一种有效量的化合物，以在哺乳动物中产生所需的治疗效果，所述化合物选自以下组合：##STR1## ，其药学上可接受的酸盐和它们的混合物，其中R.sub.1和R.sub.4分别从H和具有1至4个碳原子的烷基基团组成的组中独立选择；R.sub.2分别从H或具有1至4个碳原子的烷基基团中独立选择，或者，一起，是氧代；R.sub.3分别从H或具有1至4个碳原子的烷基基团中独立选择，或者，一起，是氧代；2-咪唑啉-2-基氨基团可以位于喹啉核的5-、6、7-或8-位置中的任何一个；而R.sub.5、R.sub.6和R.sub.7分别位于喹啉核的其余5-、6-、7-或8-位置中的一个，并且分别从Cl、Br、H和具有1至3个碳原子的烷基基团组成的组中独立选择。当这类化合物被施用于哺乳动物时，它们提供所需的治疗效果，例如收缩一个或多个血管以及通畅一个或多个鼻腔通道。
• (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using
  申请人：Allergan, Inc.

  公开号：US05077292A1

  公开（公告）日：1991-12-31

  A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals containing 1 to 4 carbon atoms, R.sub.2 and R.sub.3 are independently selected from the group consisting of H, OXO, and alkyl radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the qunioxaline nucleus and is selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow.

  从所选的化合物中选择的一种化合物，其化学式为：##STR1##及其药用可接受的酸盐，其中R.sub.1和R.sub.4独立地选自H和含有1至4个碳原子的烷基基团的组，R.sub.2和R.sub.3独立地选自H、OXO和含有1至4个碳原子的烷基基团的组，2-咪唑啉-2-基氨基团可以位于喹喔啉核的5-、6-、7-或8-位置中的任一位置，R.sub.5、R.sub.6和R.sub.7分别位于喹喔啉核的剩余5-、6-、7-或8-位置中的一个，并选自Cl、Br、H和含有1至3个碳原子的烷基基团的组。这些化合物在给哺乳动物使用时，可产生期望的治疗效果，如改变消化道液体传输速率、降低眼压和增加肾脏液体流量。
• Compounds, formulations, and methods for treating or preventing rosacea
  申请人：——

  公开号：US20040242588A1

  公开（公告）日：2004-12-02

  In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: 1 wherein each of R 1 , R 2 , and R 3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R 4 and R 5 is independently hydrogen, alkyl, or alkoxy; and each of R 6 and R 7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A 1 , A 3 , and A 4 is independently hydrogen or alkyl; and A 2 is independently hydrogen or hydroxy; and wherein each of B 1 , B 2 , and B 3 is independently hydrogen, hydroxy, or alkoxy; and each of B 4 and B 5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.

  在治疗酒渣鼻的方法、化合物和局部制剂中，包含以下公式所代表的化合物：其中R1、R2和R3中的每一个独立地是氢、卤素、烷基或烷氧基；R4和R5中的每一个独立地是氢、烷基或烷氧基；R6和R7中的每一个独立地是氢、硝基、烷基或烷氧基；A1、A3和A4中的每一个独立地是氢或烷基；A2独立地是氢或羟基；B1、B2和B3中的每一个独立地是氢、羟基或烷氧基；B4和B5中的每一个独立地是氢或烷基。将这些化合物作为喷雾、薄雾、气雾剂、溶液、乳液、凝胶、霜、药膏、糊剂、乳膏和悬浮液局部涂抹，以治疗酒渣鼻及其症状。
• [EN] A TOPICAL COMPOSITION FOR TREATING ROSACEA AND A METHOD FOR TREATING ROSACEA WITH THE SAME<br/>[FR] COMPOSITION TOPIQUE DE TRAITEMENT DE LA ROSACÉE ET PROCÉDÉ DE TRAITEMENT DE LA ROSACÉE AVEC CELLE-CI
  申请人：WHITCUP SCOTT

  公开号：WO2018218116A1

  公开（公告）日：2018-11-29

  A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.

  用于治疗酒渣鼻的复合物包括一种多激酶抑制剂，该抑制剂既抑制血管内皮生长因子受体，又抑制成纤维细胞生长因子受体。一种治疗患有酒渣鼻的患者的方法包括抑制患者的血管内皮生长因子受体；和抑制患者的成纤维细胞生长因子受体。
• Brimonidine Compositions for Treating Erythema
  申请人：Theobald Klaus P.

  公开号：US20090061020A1

  公开（公告）日：2009-03-05

  The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient.

  本发明涉及一种制药组合物，其中包括酒石酸布里莫尼定，其含量约为0.17%至0.19%的质量百分比，以药学上可接受的载体（如凝胶或乳霜）为基础。该发明还涉及一种治疗鲁米病患者皮肤红斑的方法，即通过将本发明的组合物用于患者皮肤上的红斑处进行治疗。